A Phase I trial of DSP-5336, a novel menin inhibitor, in the treatment of AML [Video]

Revumenib and ziftomenib are menin inhibitors that have shown promise in the treatment of patients with NPM1- and KMT2A-mutated acute myeloid leukemia (AML). In this video, Harry Erba, MD, PhD, Duke University, Durham, NC, introduces a novel menin inhibitor, DSP-5336, currently undergoing dose-escalation in a Phase I trial. Dr Erba anticipates that the future of menin inhibitors in AML treatment will involve their combination with chemotherapy, FLT3 inhibitors, and IDH inhibitors. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.